These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 26770967)
1. Cost-effectiveness of clopidogrel, prasugrel and ticagrelor for dual antiplatelet therapy after acute coronary syndrome: a decision-analytic model. Abdel-Qadir H; Roifman I; Wijeysundera HC CMAJ Open; 2015; 3(4):E438-46. PubMed ID: 26770967 [TBL] [Abstract][Full Text] [Related]
2. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840 [TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome. Zhao YJ; Khoo AL; Lin L; Teng M; Wu TS; Chan MY; Lim BP Value Health Reg Issues; 2016 May; 9():22-27. PubMed ID: 27881255 [TBL] [Abstract][Full Text] [Related]
5. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention. Okere AN; Ezendu K; Berthe A; Diaby V J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027 [TBL] [Abstract][Full Text] [Related]
6. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results. Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Gasche D; Ulle T; Meier B; Greiner RA Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294 [TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Strategies to Personalize the Selection of P2Y Kim K; Touchette DR; Cavallari LH; Ardati AK; DiDomenico RJ Cardiovasc Drugs Ther; 2019 Oct; 33(5):533-546. PubMed ID: 31367811 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome. Coleman CI; Limone BL Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Fu Y; Zhang XY; Qin SB; Nie XY; Shi LW; Shao H; Liu J Pharmacogenomics; 2020 Jan; 21(1):33-42. PubMed ID: 31849282 [No Abstract] [Full Text] [Related]
11. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. Chin CT; Mellstrom C; Chua TS; Matchar DB Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032 [TBL] [Abstract][Full Text] [Related]
12. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
13. Clopidogrel Versus Aspirin for the Treatment of Acute Coronary Syndrome After a 12-Month Dual Antiplatelet Therapy: A Cost-effectiveness Analysis From China Payer's Perspective. Zhang L; Lin Z; Yin H; Liu J; Xuan J Clin Ther; 2018 Dec; 40(12):2125-2137. PubMed ID: 30470579 [TBL] [Abstract][Full Text] [Related]
14. Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis. Crespin DJ; Federspiel JJ; Biddle AK; Jonas DE; Rossi JS Value Health; 2011 Jun; 14(4):483-91. PubMed ID: 21669373 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes in Canada. Grima DT; Brown ST; Kamboj L; Bainey KR; Goeree R; Oh P; Ramanathan K; Goodman SG Clinicoecon Outcomes Res; 2014; 6():49-62. PubMed ID: 24493930 [TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. Patel V; Lin FJ; Ojo O; Rao S; Yu S; Zhan L; Touchette DR Pharm Pract (Granada); 2014 Jul; 12(3):438. PubMed ID: 25243032 [TBL] [Abstract][Full Text] [Related]
17. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361 [TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Comparison between Ticagrelor and Clopidogrel in Acute Coronary Syndrome in Iran. Hashemi-Meshkini A; Tajik A; Ayati N; Nikfar S; Koochak R; Yaghoubifard S; Abbasi A; Varmaghani M J Tehran Heart Cent; 2023 Apr; 18(2):94-101. PubMed ID: 37637281 [TBL] [Abstract][Full Text] [Related]
20. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Straub N; Beivers A; Lenk E; Aradi D; Sibbing D Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]